Pharmaceutical

AusperBio AHB-137 gains breakthrough status in China for CHB  

AusperBio Therapeutics and Ausper Biopharma have received breakthrough therapy designation in China for AHB-137 for CHB.

Jul 12, 2024 - 04:00
AusperBio AHB-137 gains breakthrough status in China for CHB  
AusperBio Therapeutics and Ausper Biopharma have received breakthrough therapy designation in China for AHB-137 for CHB.
Read the original article

Tags:

Previous Article

Boehringer Ingelheim plans sustainability work for the long term

Next Article

Biotech survey highlights where industry can focus for a thriving future  

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

DEA organises Drug Take Back Day to fight addiction

DEA organises Drug Take Back Day to fight addiction

Apr 22, 2023

FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine 

FDA clears Novavax to resume trials of Covid-19 and flu...

Nov 13, 2024

NPX-267 by NextPoint Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Triple-Negative B...

Jun 14, 2024